{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"31"}]}],"title":"Diarrhea"},{"categories":[{"measurements":[{"groupId":"OG000","value":"31"}]}],"title":"Rash"},{"categories":[{"measurements":[{"groupId":"OG000","value":"26"}]}],"title":"Pain"},{"categories":[{"measurements":[{"groupId":"OG000","value":"23"}]}],"title":"Fatigue"},{"categories":[{"measurements":[{"groupId":"OG000","value":"19"}]}],"title":"Infection"},{"categories":[{"measurements":[{"groupId":"OG000","value":"19"}]}],"title":"Nausea"},{"categories":[{"measurements":[{"groupId":"OG000","value":"14"}]}],"title":"Mucositis"},{"categories":[{"measurements":[{"groupId":"OG000","value":"13"}]}],"title":"Vomiting"},{"categories":[{"measurements":[{"groupId":"OG000","value":"10"}]}],"title":"Constipation"},{"categories":[{"measurements":[{"groupId":"OG000","value":"8"}]}],"title":"Hand-foot syndrome"},{"categories":[{"measurements":[{"groupId":"OG000","value":"7"}]}],"title":"Cough"},{"categories":[{"measurements":[{"groupId":"OG000","value":"6"}]}],"title":"Acute kidney injury"},{"categories":[{"measurements":[{"groupId":"OG000","value":"6"}]}],"title":"Dry skin"},{"categories":[{"measurements":[{"groupId":"OG000","value":"6"}]}],"title":"Anorexia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5"}]}],"title":"Dehydration"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5"}]}],"title":"Edema of limb"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5"}]}],"title":"Heartburn"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5"}]}],"title":"Hyponatremia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5"}]}],"title":"Neuropathy"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Neutropenia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Febrile"}],"denoms":[{"counts":[{"groupId":"OG000","value":"44"}],"units":"Participants"}],"description":"ADVERSE EVENTS (AE) AND SERIOUS ADVERSE EVENTS (SAE) Adverse Events (AEs) will use the descriptions and grading scales found in the NCI CTCAE v3.0","groups":[{"description":"Patients receive oral lapatinib ditosylate once daily on days 1-21 and oral capecitabine twice daily on days 1-14.\n\nlapatinib ditosylate: Given orally\n\ncapecitabine: Given orally","id":"OG000","title":"Arm I"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"5 years","title":"Number of Participants With Adverse Events and Serious Adverse Events","type":"SECONDARY","unitOfMeasure":"Participants"}